Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response

J Clin Lab Anal. 2022 Nov;36(11):e24750. doi: 10.1002/jcla.24750. Epub 2022 Oct 28.

Abstract

Objective: Genetic variations can affect individual response to methadone maintenance treatment (MMT) for heroin addiction. The A118G variant (rs1799971) in the mu opioid receptor gene (OPRM1) is a potential candidate single nucleotide polymorphism (SNP) for personalized MMT. This study determined whether rs1799971 is related to MMT response or dose.

Methods: We recruited 286 MMT patients from a Han Chinese population. The rs1799971 genotype was determined via TaqMan genotyping assay. The genetic effect of this SNP on MMT response or dose was evaluated using logistic regression. A meta-analysis was performed to merge all available data to evaluate the role of rs1799971 in MMT using RevMan 5.3 software.

Results: No statistical significance was observed in the association between the OPRM1 rs1799971 and MMT response or dose in our Chinese cohort. Meta-analysis indicated that the OPRM1 A118G variation was not significantly associated with MMT response or dose requirement.

Conclusion: The results suggest that rs1799971 in OPRM1 might not play a critical role alone in influencing MMT response or dose.

Keywords: association; heroin; methadone; mu opioid receptor; rs1799971.

Publication types

  • Meta-Analysis

MeSH terms

  • Genotype
  • Heroin Dependence* / drug therapy
  • Heroin Dependence* / genetics
  • Humans
  • Methadone* / therapeutic use
  • Polymorphism, Single Nucleotide / genetics
  • Receptors, Opioid, mu / genetics

Substances

  • Methadone
  • OPRM1 protein, human
  • Receptors, Opioid, mu